Home
Knowledge Base
References
A cocktail of engineered chimeric antibodies targeting the central nervous system produces a broad-spectrum therapeutic effect for symptomatic rabies

A cocktail of engineered chimeric antibodies targeting the central nervous system produces a broad-spectrum therapeutic effect for symptomatic rabies

Zhao L, Ren Z, Wang C, Wang H, Wu Q, Hou Q, Qi X, He W, Zhang X, Wan J , Zhoui M, Fu Z (2024) A cocktail of engineered chimeric antibodies targeting the central nervous system produces a broad-spectrum therapeutic effect for symptomatic rabies. Research Square preprint. doi: 10.21203/rs.3.rs-4838561/v1

Objective: To construct and assess four chimeric human-mouse antibodies with high neutralizing activity and affinity against rabies virus (RABV), further identifying their targeted antigenic epitopes as I, II, and IV.

Summary: Results showed that combined treatment of RABV-infected mice with three SynB1-antibodies targeting different epitopes could reduce clinical symptoms and increase survival ratio to 80%. Collectively, the non-invasive brain delivery method based on hybrid antibody-conjugated cell-penetrating peptides offers a promising strategy for the effective treatment of broad-spectrum symptomatic rabies.

Usage: Saporin was suggested as a payload for SynB1 antibodies based on researchers who investigated the use of THR peptides targeting transferrin receptor protein 1 (TFR1) conjugated with drugs for the treatment of Alzheimer’s disease, APOE peptides attached to Saporin (PR-01) to target low-density lipoprotein receptor (LDLR) for glioma therapy, and the TGN peptide-Saporin, which has been studied in the field of epilepsy.